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Background and Aims. We aimed to investigate the prevalence of Giardiasis in patients with dyspepsia and patients with diabetes
mellitus. Methods. 400 patients and 100 healthy persons were included in this clinical prospective study. The number of patients
in each group was equal, 200 dyspeptic and 200 diabetic, respectively. The antigen of G. lntestinalis was determined in the stool
specimens by ELISA method. Results. The frequency of Giardiasis was 7% in dyspeptic and 15% in diabetic patients. There was no
positive results in any of the healthy persons. There was a signiﬁcant diﬀerence in prevalence rate of Giardiasis between patients
with dyspepsia and diabetes mellitus (P<0.05). Conclusions. These results revealed that the prevalence of Giardiasis in dyspepsia
and with diabetes mellitus was high in our country. This is the ﬁrst study investigating the prevalence of Giardiasis in diabetic
patients. To investigate Giardiasis in diabetic patients, who have dyspepsia or not, may be a good approach for public health.
1.Introduction
Dyspepsia is an important health problem, which leads to
signiﬁcant impairments in health-related quality of life and
has aﬀected large populations worldwide. The prevalence
rate of dyspepsia ranging from 7% to 60% were reported in
diﬀerent population-based studies [1–3].
Diabetes mellitus contributes substantially to the global
burden of disease, with an estimated 150 million people
aﬀected worldwide, and its prevalence is expected to double
by2025[4].Thereare3millionpeoplewithdiabetesmellitus
in our country [4]. Also, it is fact that, diabetic patients
have prone to infectious diseases by various mechanisms
[5, 6]. Disturbances in cellular innate immunity play a role
in the pathogenesis of the increased prevalence of infections
in DM patients. A second important mechanism is the
increased adherence of the microorganisms to diabetic cells.
Furthermore, some microorganisms become more virulent
in a high glucose environment [5, 6].
Giardia intestinalis, also termed G. Lamblia and G.
duodenalis, is a ﬂagellated protozoan initially described by
Van Leeuwenhook in 1681. It is a protozoan which most
identiﬁed from gastrointestinal tractus [7]. Transmission of
Giardia occurs by fecal-oral rout [8, 9]. That is why it has
been implicated in multiple outbreaks in high-risk groups.
High-risk groups include infants, young children and im-
munocompromised patients. The prevalence of Giardiasis
in industrialized world is 2–7% [10]. In developing coun-
tries, which have poor sanitation and hygienic conditions,
reported that prevalence rate is 40% [11, 12]. Giardiasis
typically occurs following the ingestion of water or foods
contaminated with fecal material containing cysts, and the
infectivity dose may be as low as 10 cysts. The infection
can be asymptomatic or patients may present extraintestinal
symptoms, such as fever, maculopapular rashes, pulmonary
inﬁltrates, lymphadenopathy, polyarthritis, and urticaria.
However,themostcommonsymptomsarediarrhea,abdom-
inal pain, bloating, ﬂatulence, and weight loss resulting from
malabsorption[13].Mostofthesesymptomsaresimilarwith
presenting in patients with dyspepsia. The diagnosis of Gia-
rdiasis has been classically on detection of cysts or tropho-
zoites in stool and duodenal aspirates specimens by direct2 ISRN Gastroenterology
Table 1: The demographic characteristics of study groups.
The patients
with dyspepsia
The patients
with D.
mellitus
Healthy
controls
Age (mean ± SD) 41.47 ±13.48 54.45 ±11.92 46.51±15.74
Total number (n) 200 200 100
Female sex (n%) 146 (73%) 121 (60.5%) 74 (74%)
Male sex (n%) 54 (27%) 79 (39.5%) 26 (26%)
Table 2: The distribution of prevalence rate in all study groups.P<
0.05 as considered statistical signiﬁcance.
Giardia antigen
positive (n%)
Giardia antigen
negative (n%)
P value
(compared
with controls)
Dyspepsia 14 (7%) 186 (93%) 0.007∗
Diabetes mellitus 30 (15%) 170 (85%) 0.001∗
Diabetes mellitus
with dyspepsia 11 (15.9%) 58 (84.1%) 0.001∗
Diabetes mellitus
without dyspepsia 19 (14.5%) 112 (85.5%) 0.001∗
Healthy control 0 (0%) 100 (100%)
microscopic examination and duodenal endoscopic biopsy
specimen by histologically. Recently proven, ELISA methods
for the detection of Giardia-speciﬁc antigen in fecal speci-
mens have 97.5% sensitivity and 99.5% speciﬁcity [14, 15].
Since Giardiasis is an etiologic cause of dyspepsia and
immuncomopromised patients, such as diabetics have prone
to Giardiasis, we hypothesized that determination of preva-
lence rate may be useful for public health. For this purpose,
we designed this clinical prospective study.
2.MaterialsandMethods
This was a prospective, single-center study. A total of 200
dyspeptic patients (male/female: 54/146) and 200 diabetic
patients (male/female: 79/121), who were admitted to
G¨ oztepe Training and Research Hospital, outpatient clinics
of Gastroenterology and Internal Medicine between July
2008 and January 2009, were enrolled into the study. 100
healthy subjects (male/female: 26/74) without any gastroin-
testinal complaints served as controls. The diabetic patients
were divided into subgroups: patients with dyspepsia (n =
69) and without dyspepsia (n = 131).
Written informed consent was obtained from all par-
ticipants. The study protocol was approved by the Local
Research Ethics Committee. Dyspepsia and diabetes mellitus
was deﬁned according to the Criteria of Rome III consensus
report and American Diabetes Association, respectively.
The patients who have any gastrointestinal malignancy
and immunosuppressive condition were excluded. Demo-
graphic characteristics of patients and healthy subjects are
shown in Table 1.
Age, sex, symptoms, ﬁndings of history, and physical
examination were recorded. The determination of Giardia-
speciﬁc antigen in stool specimens were done by ELISA
Table 3: The distribution of the prevalence rate of Giardiasis and
comparative signiﬁcance level in all study groups. ∗P<0.05, ∗∗P<
0.01. D. M = D. Mellitus.
Giardia antigen
(+) (n%)
Giardia antigen
(–) (n%)
P
Dyspepsia 14 (7%) 186 (93%) 0.011∗
D. mellitus 30 (15%) 170 (85%)
Dyspepsia 14 (7%) 186 (93%) 0.007∗∗
Control 0 (0%) 100 (100%)
Dyspepsia 14 (7%) 186 (93%) 0.027∗
D. M + dyspepsia (+) 11 (15.9%) 58 (84.1%)
Dyspepsia 14 (7%) 186 (93%) 0.026∗
D. M + dyspepsia (−) 19 (14.5%) 112 (85.5%)
D. mellitus 30 (15%) 170 (85%) 0.001∗∗
Control 0 (0%) 100 (100%)
D. mellitus 30 (15%) 170 (85%) 0.851
D. M + dyspepsia (+) 11 (15.9%) 58 (84.1%)
D. mellitus 30 (15%) 170 (85%) 0.901
D. M + dyspepsia (−) 19 (14.5%) 112 (85.5%)
Control 0 (0%) 100 (100%) 0.001∗∗
D. M + dyspepsia (+) 11 (15.9%) 58 (84.1%)
Control 0 (0%) 100 (100%) 0.001∗∗
D. M + dyspepsia (−) 19 (14.5%) 112 (85.5%)
method with Generic Assays GmbH kit (Ludwing-Erhard-
Ring 3, 15827, Germany).
All data were collected and analyzed with NCSS 2007
& PASS 2008 Statistical Software (Utah, USA). One way
Annova test was used to compare the patient and control
groups for the normally distributed parameters. Statistical
signiﬁcance between the groups was determined using the
chi-square and Fisher’s exact test. P value less than 0.05 was
considered statistically signiﬁcant.
3. Results
This study was performed with 400 patients (200 dyspeptic
and 200 diabetic) and 100 healthy subjects between July
2008 and January 2009. Table 1 shows the demographic
characteristics of the study groups.
The prevalence of Giardiasis was found 7% (14/200) in
dyspeptic patients and 15% (30/200) in diabetic patients.
There was no positive result of Giardia antigen in any of the
healthy subjects. There is a signiﬁcant diﬀerence in preva-
lence rate between the study groups and the control group
(P<0.05).
The frequency of Giardia antigen positivity was found
15.9% (11/69) in diabetic patients with dyspepsia and 14.5
(19/112) without dyspepsia. There was no statistical signiﬁ-
cantdiﬀerencebetweenthetwogroups(P>0.05).Therewas
a signiﬁcant diﬀerence in terms of the prevalence of Giardia-
sis between diabetic and dyspeptic patients (P<0.05). The
prevalence of Giardiasis in patients with diabetes mellitus
was higher than patients with dyspepsia. Table 2 shows the
distribution of prevalence rate in all study groups. Table 3
shows the comparative prevalence rate in all study groups.ISRN Gastroenterology 3
Table 4: Distribution of the symptoms of patients with dyspepsia.
Symptoms n (number) % (percentage)
Bloating 172 86
Abdominal pain 142 71
Heartburn 121 60.5
Abdominal discomfort 97 48.5
Abdominal fullness 70 35
Nausea 50 25
Early satiety 42 21
Constipation 34 17
Diarrhea 19 9.5
There was no signiﬁcant relationship between patient’s
symptoms and Giardia frequency (P>0.05). The frequency
ofsymptomsinpatientswithdyspepsiaanddiabetesmellitus
are shown Tables 4 and 5, respectively. As it shown, diarrhea
is not common symptom in each study group. Table 6 shows
the distribution of the symptoms according to Giardia anti-
gen results in patients with dyspepsia. There was only slight
signiﬁcant diﬀerence in patients suﬀering from heartburn
(P = 0.049).
4. Discussion
Giardiasis is a common infection in our country, such as
w o r l d w i d e .T h ep r e v a l e n c er a t ew a sr e p o r t e d2 – 7 %a si n
developed and 40% in developing countries, respectively
[10, 16]. The prevalence was higher in the countries that
lack proper sanitation and hygienic conditions than other
parts of the world. For this reason, we hypothesized that the
prevalence was high in our country. Diabetes mellitus and
dyspepsia were distinct clinical entity which aﬀected a very
large population worldwide. We investigated the prevalence
rate of Giardiasis in dyspeptic and diabetic patients. This
study is the ﬁrst investigating the prevalence of Giardiasis in
patients with diabetes mellitus.
In 2006, Grazioli et al. reported that the prevalence of
Giardiasis was 6.5% (9/137) in patients with dyspepsia and
irritable bowel syndrome [17]. This prevalence rate has been
reported 15.5% by Carr Jr. et al. [18]. In a study, reported
from Egypt, which is an endemic area, the prevalence was
found 44% (96/220) in patients with dyspepsia [19]. There
are several reports from diﬀerent countries and investigators
[11, 20].
In our study, the prevalence rate of Giardiasis was deter-
mined 7% (14/200) in dyspeptic and 15% [30/200] in dia-
betic patients. Also, in 69 subjects of diabetics have dyspeptic
symptoms, and prevalence rate of Giardiasis was found
15.9% (11/69) in this subgroup. There was no signiﬁcant dif-
ference between diabetic patients with or without dyspepsia
(P>0.05). There was no positive results of Giardia antigen
in any of the healthy subjects. This ﬁnding has been provided
a good evidence for positive correlation between dyspepsia
and Giardiasis.
In previous studies reported that dyspeptic symptoms
(e.g., abdominal pain and discomfort) are more common
Table 5: Distribution of the symptoms in diabetic patients with
dyspepsia.
Symptoms n (number) % (percentage)
Bloating 59 29.5
Heartburn 59 29.5
Abdominal pain 44 22
Abdominal discomfort 34 17
Abdominal fullness 26 13
Early satiety 16 8
Constipation 12 6
Nausea 5 2.5
Diarrhea 4 2
Table 6:DistributionofthesymptomsaccordingtoGiardiaantigen
results in patients with dyspepsia.
Symptoms Giardia antigen
(+) n (%)
Giardia antigen
(−) n (%) P value
Bloating 14 (100%) 158 (84.9%) 0.117
Abdominal pain 8 (57.1%) 134 (72%) 0.236
Abdominal
discomfort 5 (35.7%) 92 (49.5%) 0.321
Nausea 5 (35.7%) 45 (24.2%) 0.337
Heartburn 5 (35.7%) 116 (62.4%) 0.049∗
Constipation 3 (21.4%) 31 (16.7%) 0.647
Abdominal
fullness 2 (14.3%) 68 (36.6%) 0.092
Early satiety 1 (7.1%) 41 (22%) 0.187
Diarrhea 1 (7.1%) 18 (9.7%) 0.755
∗Fisher’s exact test: P<0.05.
thandiarrhea in patientswithGiardiasis [17,19].Ourresults
supported this ﬁnding. In our study, patients with Giardiasis
more commonly presented with dyspeptic symptoms than
diarrhea (Table 6). Therefore, an important ﬁnding of this
prospective study is that there was no relationship between
dyspeptic symptoms and Giardiasis.
Our results suggested that the frequency of Giardiasis
in dyspepsia was lower than that reported from endemic
country. A slight increase was observed when compared to
the results in western populations. There was no published
research to compare the prevalence of Giardiasis in diabetic
patients observed in this study.
In conclusion, the prevalence of Giardiasis is high in
patients with dyspepsia and diabetes mellitus. To investigate
thecausesofdyspepsia,itshouldbeconsideredtheGiardiasis
as an etiologic factor. This approach will be useful in diagno-
sis and management of dyspepsia.Taking into consideration
the high frequency of Giardiasis in diabetic patients with or
withoutdyspepsia,wespeculatethatsearchingGiardiasiswill
be a good approach for public health.4 ISRN Gastroenterology
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